CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Amlodipine +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03461003
NCT03461003Phase 4Completed

A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension

The University of Texas Health Science Center, Houston·interventional·Posted Mar 9, 2018·Updated Sep 9, 2022

In Brief

A Phase 4 clinical trial evaluating NICHE method, Usual care, and 4 other interventions for Pediatric Hypertension. Completed, enrolled 49 participants across 1 site.

Detailed Summary

The single patient (n-of-1) randomized trial is an underused approach to resolving therapeutic uncertainty by using a patient's own data to inform an individualized treatment plan. The proposed research is designed to assess whether the n-of-1 trial approach improves blood pressure control compared to usual care. This trial aims to advance learning about not only the treatment of pediatric hypertension but also the use of a neglected type of randomized trial to optimize the care of each patient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMar 9, 2018
Enrollment StartApr 2, 2018
Primary CompletionNov 14, 2020
Study CompletionMay 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.3 years ago

Interventions

NICHE methodother

Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.

Usual careother

Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.

Amlodipinedrug

Calcium-channel blocker; antihypertensive

Lisinoprildrug

Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive

Hydrochlorothiazidedrug

Thiazide diuretic; antihypertensive

Losartandrug

Angiotensin II receptor blocker (ARB); antihypertensive